DiMeN Doctoral Training Partnership: Drug discovery for the inherited ciliopathy and cystic kidney disease nephronophthisis


   MRC DiMeN-XL Doctoral Landscape Award

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
Prof J Sayer, Dr C Miles  No more applications being accepted  Competition Funded PhD Project (European/UK Students Only)

About the Project

Joubert syndrome is a ciliopathy syndrome giving rise to a brain, retinal and renal phenotype. The renal disease manifests as childhood cystic kidney disease and nephronophthisis. We have developed and characterised several models of Joubert Syndrome caused by mutations in CEP290, a gene encoding a ciliary and centrosomal protein. Disease models include a whole animal mouse mutant, mouse collecting duct cell lines carrying Cep290 mutation and human patient-derived renal epithelial cells which are CEP290 deficient.

Using these models we have identified abnormalities of the primary cilium and of developmental signalling pathways, which lead to the kidney phenotype. More recently we have demonstrated that chemical agonists of the Hedgehog signalling pathway can (i) restore normal organoid development to Joubert syndrome patient urine-derived renal epithelial cells, (ii) restore normal organoid development to collecting duct cells derived from Cep290 mutant mice, and (iii) reduce the development of kidney cysts in Cep290 mutant mice. Furthermore, in all three cases, abnormal primary cilium structure is partially rescued / restored [http://www.ncbi.nlm.nih.gov/pubmed/24946806].

We have recently also identified an additional pathophysiological feature of nephronophthisis caused by CEP290 mutation where an abnormal DNA damage response is observed [http://www.ncbi.nlm.nih.gov/pubmed/26301811].

To verify disease mechanisms and drug targets relevant to DNA damage and the cell cycle, additional model systems are needed as our existing models have limitations: (i) human patient-derived cells have a very limited capacity for cell culture, (ii) mouse collecting duct cells carry an “immortalising” gene and thus are not a physiologically appropriate model for cell cycle analyses, and (iii) whole animals are not appropriate for early (and large scale) drug discovery work.
Consequently, we will exploit the use of primary embryonic fibroblasts isolated from our Cep290 mutant mice, as well as Joubert syndrome patient fibroblasts. Such cells can be extensively passaged and expanded in culture without additional manipulations. As such, they are an ideal system with which to identify drug targets for nephronophthisis.

Cell culture systems will be established for drug treatment (using panels of drug suitable for repurposing). Phenotypic readouts of ciliary length and structure as well as cell-cell junctions will be assayed using fluorescent and confocal microscopy. Pathway analysis including Hh pathway, Wnt signalling, DNA damage response will be assayed using qPCR and Western blotting. Unbiased transcriptomic and proteomic approaches in mutant vs. wild-type cells will be performed to identify novel pathways and therapeutic approaches. Work will be performed in Newcastle (additional supervisor Dr Kathryn White, imaging specialist) and will utilise existing collaborations with pharma (Pierre Saint-Mezard, Novartis).

Funding notes:
DiMeN (Discovery Medicine North) DTP studentships are funded for 3.5 years and include the following annual package of financial support over the duration of the studentship:
•A tax-free maintenance grant set at the UK Research Council’s national postgraduate rate
•Full payment of tuition fees at the Home/EU rate
•A research training support grant (RTSG) to support your research studies (managed through the host institution)
•Opportunity to apply to our Flexible Fund to enable you to attend training workshops and visit research groups to advance your skills training.

Successful Home students will receive a full studentship. EU students will be considered for a full studentship or just fee support depending on the excellence of their qualifications and their employment/residency status (http://www.mrc.ac.uk/skills-careers/studentships/studentship-guidance/student-eligibility-requirements/). Overseas students are not eligible to apply.

Entry requirements:
You should be someone with an outstanding academic track record and can demonstrate your potential for the research project of your choice.
You must hold (or be expected to hold by October 2016) a First or a good 2:1 UK undergraduate degree, a suitable qualification at Masters level or an equivalent degree from a recognised EU institution, in the biosciences or a related area. The multidisciplinary training experience and interdisciplinary nature of some of our projects means that we welcome applications from students with physical science and/or mathematical backgrounds who are interested in using their skills to address the challenges of 21st century bioscience research.

How to apply:
Please carefully read the instructions on how to apply at our website and use the link on the page to apply: http://www.dimen.org.uk/how-to-apply/application-overview

 About the Project